NurExone Biologic Inc News - J90

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma

TORONTO and HAIFA, Israel, July 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

Updates from NurExone: Growth Conference Presentation and Website Relaunch

TORONTO and HAIFA, Israel, July 05, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market

TORONTO and HAIFA, Israel, June 28, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

TORONTO and HAIFA, Israel, June 21, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application

TORONTO and HAIFA, Israel, June 11, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders

TORONTO and HAIFA, Israel, June 04, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

TORONTO and HAIFA, Israel, May 29, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF...

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

TORONTO and HAIFA, Israel, May 17, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX), (OTCQB:...

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

TORONTO and HAIFA, Israel, April 25, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

TORONTO and HAIFA, Israel, April 19, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

TORONTO and HAIFA, Israel, April 02, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

TORONTO and HAIFA, Israel, March 27, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

TORONTO and HAIFA, Israel, March 22, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

TORONTO and HAIFA, Israel, March 15, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

TORONTO and HAIFA, Israel, March 08, 2024 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (Germany:...

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

NurExone Biologic Inc (J90)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

J90 News

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma

Updates from NurExone: Growth Conference Presentation and Website Relaunch

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

J90 Discussion

Your Recent History

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

NurExone Biologic Inc (J90) News

NurExone Biologic Inc (J90)

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

J90 News

Promising Preliminary Results in Optic Nerve Recovery Study of NurExone’s first product ExoPTEN for Glaucoma

Updates from NurExone: Growth Conference Presentation and Website Relaunch

NurExone’s ExoPTEN Being Studied as Glaucoma Treatment for US$3.4 Billion Market

On Path to First-in-Human Study, NurExone Engages Prominent Expert in Biological Drug Development

NurExone Announces Expansion of ExoPTEN Patent Coverage with Notice of Allowance for Japanese Patent Application

NurExone Announces Voting Results from 2024 Annual Meeting of Shareholders

NurExone Reports First Quarter 2024 Financial Results and Provides Corporate Update, moving forward with FDA guidelines for the Human Trials

NurExone Welcomes Biopharma Exec Dr. Ram Petter to Drive Strategic Collaborations

NurExone Biologic Inc. Announces Strategic Expansion to US Financial Markets with Approval of OTCQB Listing Application and DTC Eligibility

NurExone Presenting on Revolutionary Spinal Cord Injury Therapy at European Conference on Exosomes and Regenerative Medicine

NurExone Reports Fourth Quarter and Year Ended December 31, 2023 Financial Results and Provides Company Update

Gross Proceeds Close of $4M CAD Generated for NurExone From Warrants Exercise

In Preparation for Expected Human Clinical Trials, NurExone Signs Agreement for Large Scale Preclinical Testing for Its Spinal Cord Injury Therapy, ExoPTEN

NurExone's Strategic Update: Submission of OTCQB Listing Application to Initiate US financial presence

NurExone establishing State-of-the-Art Research and Development Facility in Haifa, Israel

J90 Discussion

Your Recent History